Ascrinvacumab
Tools
Actions
General
Print/export
In other projects
Appearance
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by DMacks (talk | contribs) at 03:35, 21 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 03:35, 21 June 2020 by DMacks (talk | contribs) (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB))
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | activin receptor-like kinase 1 |
Clinical data | |
Other names | PF-03446962 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6396H9850N1694O2012S44 |
Molar mass | 144079.64 g·mol−1 |
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by Pfizer Inc.
References
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
---|---|---|---|---|---|---|---|---|---|
Bone |
| ||||||||
Musculoskeletal |
| ||||||||
Circulatory |
| ||||||||
Neurologic |
| ||||||||
Angiogenesis inhibitor |
| ||||||||
Growth factor |
| ||||||||
|
Type I |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Type II |
| ||||||||||||||
Type III |
| ||||||||||||||
Unsorted |
|